340B Health

Why 340B Matters

New: 340B Hospitals Use Their Contract Pharmacy Benefit to Treat Low-Income and Rural Patients: Results from a Survey of 340B Health Members

A survey of 340B Health member hospitals demonstrates that 340B hospitals rely on their contract pharmacy benefit to treat their low-income and rural patients. The findings also indicate that eliminating or reducing the contract pharmacy program could reduce the level of services 340B hospitals are able to provide to patients in need. Read the report and click here for an overview of the report’s findings, and click here for an infographic summarizing the findings.

New: Assessing the Financial Impact of the 340B Drug Pricing Program on Drug Manufacturers

340B Health commissioned the research firm Dobson DaVanzo & Associates to assess the financial impact of 340B discounts on drug manufacturers and evaluate the plausibility of claims that the 340B Program is a cause of pharmaceutical price increases, cost shifting, and reductions in private sector research and medical discovery. The analysis found that the 340B Program cannot plausibly be a major driver of U.S. drug spending or a major cause of cost shifting by drug manufacturers to make up for 340B discounts. Read the report and click here for an overview of the report’s findings, and click here for an infographic summarizing the findings.

340B Infographics

Click here to see infographics highlighting 340B disproportionate share (DSH) hospitals, including their treatment of low-income patients and their provision of uncompensated care and specialized services.

Impact Profiles

See how hospitals use 340B savings to help vulnerable patients. Read more.

Faces of 340B

340B is more than a drug purchasing program. It’s a life saver for vulnerable uninsured and underinsured patients. Read more.

Videos: Why 340B matters

Watch as hospital providers from across the country explain how access to 340B drug discounts enables their institutions to fulfill their safety-net mission. Watch the videos.

Financial Challenges Faced by 340B Disproportionate Share Hospitals In Treating Low-Income Patients

340B Health commissioned the research firm Dobson DaVanzo & Associates to evaluate the financial challenges faced by disproportionate share (DSH) hospitals participating in the 340B drug discount program due to their characteristics as safety net hospitals and their unique patient populations. Read the report.
 

Analysis of the Proportion of 340B DSH Hospital Services Delivered to Low-Income Oncology Drug Recipients Compared to Non-340B Providers

340B Health commissioned the research firm Dobson DaVanzo & Associates to evaluate whether 340B disproportionate share (DSH) hospitals treat a higher proportion of low income oncology drug recipients than do non 340B providers. Read more.

Analysis of 340B Disproportionate Share Hospital Services Delivered to Vulnerable Patient Populations
340B Health commissioned the research firm Dobson DaVanzo & Associates to conduct an analysis of hospitals using 2014 Medicare cost report data to determine the extent to which 340B disproportionate share (DSH) hospitals are targeting their services to vulnerable patient populations. Read more.

Analysis of Patient Characteristics among Medicare Recipients of Separately Billable Part B Drugs from 340B DSH Hospitals and Non-340B Hospitals and Physician Offices

340B Health commissioned the research firm Dobson DaVanzo & Associates to conduct an analysis of providers in the Medicare Part B drug market to examine demographics. Read more.

340B Program Helps Hospitals Provide Services to Vulnerable Patients: Results from a Survey of 340B Health Members

The program funds free and reduced-price medications for the needy – and much more. From neighborhood clinics to medication management services and even patient transportation to hospitals, 340B savings improve the health of underserved Americans every day. Read the report.

HRSA's Proposed Omnibus Guidance Would Jeopardize 340B Hospitals: Results from a Survey of 340B Health Members

The Health Resources and Services Administration’s 2015 proposed guidance on the 340B Drug Pricing Program may have intended to cut through previous confusion in the administration of the program, but a survey of 340B Hospitals indicates the proposed guidance would cause significant harm to hospitals that rely on 340B to provide critical care in their communities. Read the report.